Gastroenterology

Top Medical News
3 days ago
Individuals with a family history of Barrett's oesophagus or oesophageal adenocarcinoma (OAC) are at risk of developing the said diseases, according to the results of a systematic review and meta-analysis.
3 days ago
Patients on uninterrupted periprocedural antithrombotic therapy have a negligible risk of significant bleeding associated with the placement of a percutaneous endoscopic gastrostomy (PEG) tube, a recent study has shown.
3 days ago
In the treatment of older patients with inflammatory bowel disease (IBD), vedolizumab is linked to a lower risk of infection-related hospitalization compared with antitumour necrosis factor-α (anti-TNF) agents, according to a study.
4 days ago
Clinical remission, endoscopic remission, and biomarker normalization show a positive association with adalimumab trough levels in patients with inflammatory bowel disease (IBD), reports a study. Moreover, adalimumab levels of ≥8.25 μg/mL correlate with deep remission.
Pearl Toh, 5 days ago
The potassium-competitive acid blocker vonoprazan appears to be more effective than proton pump inhibitors (PPIs) in healing severe erosive esophagitis and relieving the symptoms of gastroesophageal reflux disease (GERD), according to a meta-analysis presented at APDW 2021.
5 days ago
Cannabis and cannabinoids are not effective in inducing clinical remission or reducing inflammation in patients with inflammatory bowel disease (IBD), but they appear to significantly improve patient-reported symptoms and quality of life (QOL), suggest the results of a systematic review and meta-analysis.
Audrey Abella, 5 days ago
A 14-day quadruple therapeutic regimen containing vonoprazan – a first-in-class potassium-competitive acid blocker (P-CAB) with reportedly stronger acid inhibition than proton pump inhibitors – provided an excellent cure rate for Helicobacter pylori (H. pylori) infection in patients with high clarithromycin and quinolone resistance regardless of CYP3A4/5 genotypic polymorphism, according to the prospective VQ-HP trial presented at APDW 2021.
Special Reports
12 Mar 2021
SALOFALK – Mesalazine 1.5 g PR granules
10 Mar 2020
RB Health is committed to support healthcare quality improvement through CME activities that help physicians stay updated with the latest developments in medicine. At the RB symposium held in Kuala Lumpur, two distinguished speakers gave their insights into the management of acid reflux and sore throat – two of the most common reasons for patients to visit their doctors.
26 Nov 2019
At the recent Takeda Malaysia Vocinti® (vonoprazan) launch, held in conjunction with the Annual Scientific Meeting of the Malaysian Society of Gastroenterology and Hepatology - GUT 2019 at Shangri-La Kuala Lumpur, Professor Akihito spoke about vonoprazan’s merits as an alternative to conventional proton pump inhibitors.
Dr Raghav Sundar, 09 Sep 2019

Overall survival (OS) is currently the primary criteria in assessing the efficacy of a cancer treatment. Dr Raghav Sundar, a consultant medical oncologist at the National University Hospital, Singapore, details the crucial role played by tumour response in evaluating treatment efficacy, with a focus on the multiple kinase inhibitor lenvatinib in the treatment of hepatocellular carcinoma (HCC).  

Dr Joslyn Ngu, 04 Dec 2017

Advancements in genomics has paved the way for better classifications of colorectal cancers (CRC) and the use of precision therapy.

12 Jul 2017
DUKORAL – Inactivated Vibrio cholerae O1 serogroup & recombinant cholera toxin B subunit (WC/rCTB) vaccine (oral) – AJ Biologics
04 Jan 2017
Recently, randomized controlled trials and guidelines have brought to light the benefits of extending the duration of H. pylori treatment. Below are summaries of guidelines and trials examining the regimens used to manage the infection.
Conference Reports
Pearl Toh, 14 Sep 2021
The potassium-competitive acid blocker vonoprazan appears to be more effective than proton pump inhibitors (PPIs) in healing severe erosive esophagitis and relieving the symptoms of gastroesophageal reflux disease (GERD), according to a meta-analysis presented at APDW 2021.
Audrey Abella, 14 Sep 2021
A 14-day quadruple therapeutic regimen containing vonoprazan – a first-in-class potassium-competitive acid blocker (P-CAB) with reportedly stronger acid inhibition than proton pump inhibitors – provided an excellent cure rate for Helicobacter pylori (H. pylori) infection in patients with high clarithromycin and quinolone resistance regardless of CYP3A4/5 genotypic polymorphism, according to the prospective VQ-HP trial presented at APDW 2021.
Audrey Abella, 13 Sep 2021
According to a Hong Kong study presented at APDW 2021, the use of proton pump inhibitors (PPIs) is not associated with adverse clinical outcomes in individuals with COVID-19.
Elaine Soliven, 10 Sep 2021
The combination of reduced-dose S1 and oxaliplatin (SOx) chemotherapy preserves quality of life (QoL) and physical function in vulnerable older patients with metastatic colorectal cancer (mCRC), according to a subgroup analysis of the NORDIC9* study presented at ESMO GI 2021.
Roshini Claire Anthony, 09 Sep 2021

Antibiotic exposure may be associated with an increased risk of early-onset colorectal cancer (CRC), according to a study from Scotland presented at ESMO GI 2021.

Jairia Dela Cruz, 09 Sep 2021
The treatment of gastroesophageal reflux disease (GERD) continues to rely on proton pump inhibitors (PPIs), but advances in the field take account of new management options, such as antireflux surgery for reflux hypersensitivity and diaphragmatic breathing in refractory GERD or rumination, as pointed out during a lecture presented at this year’s virtual Asian Pacific Digestive Week (APDW 2021).
Tristan Manalac, 09 Sep 2021
During the coronavirus disease 2019 (COVID-19) pandemic, burnout has become prevalent among gastroenterologists in Southeast Asia, driven strongly by fears of getting infected and the stress of reduced income, according to a Singapore study presented at the recently concluded Asian Pacific Digestive Week 2021 (APDW 2021).